MyWay HRT Range Overview and Stock Availability
Stock Status Key
Dear Healthcare Professional,
Earlier this year, Viatris informed you that our third-party manufacturing partner was experiencing an interruption in the production of Elleste™, which included; Elleste Solo™ (1mg & 2mg), Elleste Duet™ (1mg & 2mg) and Elleste Duet™ Conti (2mg).
At that time, we anticipated a temporary interruption and for stock levels to resume during the middle of 2019. To minimise disruption to patients and to support pharmacies, societies and healthcare professionals (HCPs) across the country we took several proactive steps, including:
- • sending two Elleste™ stock constraint mailers to 50,000+ HCPs;
- • informing the British Menopause Society;
- • continuously communicating with the National Pharmacy Association; and
- • creating a MyWay Pharmacist leaflet for our salesforce to use when visiting pharmacists across the country.
In addition, we created a new promotional page on our dedicated HCP website, called MyWay HRT Overview and Stock Availability. This page provides details of our range of HRT products, stock availability and options to switch patients to alternative products where appropriate.
To ensure the stable supply of Elleste™ Oral Tablets in the future, Viatris will be transferring the production of Elleste™ to a Viatris owned and operated facility.
The site transfer is in progress and we anticipate production to resume by second half of 2020. In the meantime, any stock of Elleste™ Oral Tablets in the market, is available to order and prescribe. Once that supply has been depleted, the replenishment of Elleste™ Oral Tablets will not be available until the site transfer process has been completed.
We will continue to support pharmacies, societies and healthcare professionals by providing updates to our materials and communications including updates to stock availability, timing for resolution and information about Viatris other HRT products.
Please note that this does not affect the transdermal patches; Elleste Solo™ MX (40 and 80mcg).
Information for Prescribers
Viatris is unable to make any specific treatment recommendations to healthcare professionals or individual patients. We would like to highlight that there are other Hormone Replacement Therapy products in our portfolio which are available, please visit mywayhub.co.uk/en-gb/range or www.mylanconnects.co.uk for more information. Please note these are promotional websites and contain information on Viatris products.
For enquiries in relation to availability of a product, please contact our Customer Service team on, +44 (0)1707 853 100 or firstname.lastname@example.org. For medical information enquiries, please contact Viatris medical information team on +44 (0)1707 853000 (option 1) or email@example.com.
Dr Ken Tam
Senior Medical Advisor
Elleste is a hormone replacement therapy (HRT) for oestrogen deficiency symptoms in post and peri-menopausal women.
Elleste Solo™ 1mg – Patient Information Leaflet and SmPC
Elleste Solo™ 2mg – Patient Information Leaflet and SmPC
Elleste Duet™ 1mg – Patient Information Leaflet and SmPC
Elleste Duet™ 2mg – Patient Information Leaflet and SmPC
Elleste Duet™ Conti 2mg – Patient Information Leaflet and SmPC
Date of preparation: August 2019
Progestogenic Side Effect Profiles1
Receptor side effects2,3,4
Why go low?